Want to see IN:BIOCON full AI Analyst Report?

Biocon Limited (BIOCON) Price & Analysis

16 Followers

BIOCON Stock Chart & Stats

₹433.70

₹2.60(0.60%)

At close: Jul 27 4:00 PM EDT

₹433.70

₹2.60(0.60%)

Day’s Range― - ―

52-Week Range₹331.00 - ₹447.00

Previous CloseN/A

Volume2.57M

Average Volume (3M)208.50K

Market Cap

₹693.01B

Enterprise Value₹714.88K

Total Cash (Recent Filing)₹38.83B

Total Debt (Recent Filing)₹154.34B

Price to Earnings (P/E)152.6

Beta0.71

Next Earnings

Aug 05, 2026

EPS Estimate

1.01

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)2.79

Shares Outstanding1,629,694,100

10 Day Avg. Volume177,351

30 Day Avg. Volume208,504

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)1.45

Price to Sales (P/S)2.92

P/FCF Ratio-94.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)7.92

Revenue Forecast (FY)₹199.39B

Bulls Say, Bears Say

Bulls Say

Revenue Growth TrajectoryConsistent multi-year revenue expansion (Fundamentals.RevenueGrowth ~10.9%) indicates durable demand across Biocon’s products and services. Sustained top-line growth supports scale economies, ongoing R&D investment and capacity utilization that matter over the next 2–6 months.

Improving Capital StructureA materially lower debt-to-equity (~0.45) versus prior years reduces financial leverage risk and interest burden, improving funding flexibility. This stronger balance-sheet footing enhances resilience to cash-flow volatility and supports strategic investment or partnership options.

Diversified Biopharma Revenue StreamsMultiple revenue pillars (biosimilars, complex generics, biologics/CDMO services, licensing) lower single-product concentration risk. Diversification supports steadier cashflows, cross-selling and reuse of manufacturing assets, making core economics more durable across market cycles.

Bears Say

Margin CompressionSharp erosion of gross and net margins reduces fundamental earnings power and limits retained cash for reinvestment. Persistent margin pressure would impair ability to fund R&D and commercialization, raising execution risk and weakening long-term profitability sustainability.

Weak Cash Generation / Negative Free Cash FlowNegative free cash flow (~-5.2B) and falling operating cash flow mean earnings are not converting to cash reliably. Over months this raises funding needs, could force external financing or cutbacks, and reduces margin of safety for capital spending and milestone investments.

Very Low Return On EquityROE near 1.1% signals weak capital efficiency and poor translation of revenue into shareholder returns. Persistently low ROE constrains long-term capital allocation, investor confidence and the company’s ability to self-fund growth initiatives without dilutive or costly financing.

Biocon Limited News

Biocon Wins Health Canada Approval for Yesintek Ustekinumab Autoinjector Pen

Biocon Limited ( ($IN:BIOCON) ) has issued an announcement. Biocon’s Canadian subsidiary has received Health Canada’s Notice of...

6d ago

Biocon makes Biocon Biologics a wholly owned unit via share swap

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has acquired 11,536,956 equity shares of its...

1M ago

Biocon Makes Biocon Biologics Wholly Owned Via Preferential Share Issue

An announcement from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has completed the acquisition of...

1M ago

Biocon Closes Insider Trading Window Ahead of June Quarter Results

Biocon Limited ( ($IN:BIOCON) ) has shared an update. Biocon Limited has announced the closure of its trading...

1M ago

Biocon Deepens Malaysia Diabetes Push as Partner Wins MYR 225 Million Insulin Tenders

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon has reinforced its presence in Malaysia’s diabetes care...

1M ago

Biocon Sets Final Dividend and Outlines TDS Rules for FY 2025-26 Payout

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has informed shareholders that its board has...

1M ago

Biocon Subsidiary Wins Health Canada Nod for Antifungal Micafungin Injection

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Pharma Limited, a subsidiary of Biocon...

3M ago

Biocon Seeks Shareholder Nod for Leadership Changes and Preferential Share Issue via E-Voting

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited has initiated a postal ballot...

3M ago

Biocon Reshapes Board and Governance as It Integrates with Biocon Biologics

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon’s board approved the audited standalone and consolidated financial...

3M ago

Biocon Delivers Double-Digit Growth in Q4 as Biosimilars Lead Revenue Gains

Biocon Limited ( ($IN:BIOCON) ) has issued an update. Biocon reported consolidated Q4FY26 total income of Rs 4,569...

3M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹331.00 and its highest was ₹447.00 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹693.01B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is Aug 05, 2026 which is tomorrow.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on May 07, 2026. The company reported ₹1.2 earnings per share for the quarter, beating the consensus estimate of ₹1.174 by ₹0.026.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 1.01.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,629,694,100 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹1.2 in its last earnings report, beating expectations of ₹1.174. Following the earnings report the stock price went up 0.486%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.